Matches in UGent Biblio for { <https://biblio.ugent.be/publication/870320#aggregation> ?p ?o. }
Showing items 1 to 36 of
36
with 100 items per page.
- aggregation classification "C3".
- aggregation creator B53676.
- aggregation creator B53677.
- aggregation creator B53678.
- aggregation creator B53679.
- aggregation creator B53680.
- aggregation creator B53681.
- aggregation creator B53682.
- aggregation creator B53683.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2009".
- aggregation hasFormat 870320.bibtex.
- aggregation hasFormat 870320.csv.
- aggregation hasFormat 870320.dc.
- aggregation hasFormat 870320.didl.
- aggregation hasFormat 870320.doc.
- aggregation hasFormat 870320.json.
- aggregation hasFormat 870320.mets.
- aggregation hasFormat 870320.mods.
- aggregation hasFormat 870320.rdf.
- aggregation hasFormat 870320.ris.
- aggregation hasFormat 870320.txt.
- aggregation hasFormat 870320.xls.
- aggregation hasFormat 870320.yaml.
- aggregation isPartOf urn:issn:1359-6535.
- aggregation language "eng".
- aggregation publisher "INT MEDICAL PRESS LTD".
- aggregation title "Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools".
- aggregation abstract "Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the USA) is the first agent in the new class of oral HIV-1 entry inhibitors to acquire approval by the US Food and Drug Administration and the European Medicine Agency. Considering the mechanism of action, it is expected that this drug will be effective only in a subpopulation of HIV-1-infected people, namely those harbouring the R5 virus. The favourable toxicity profile of the drug has been demonstrated in Phase III clinical trials in treatment-naive (MERIT) and treatment-experienced (MOTIVATE) patients. In the latter population, maraviroc showed a superior antiviral efficacy and immunological activity compared with optimized backbone therapy+placebo. However, in MERIT, a prospective double-blind, randomized trial in treatment-naive patients, maraviroc+zidovudine/lamivudine failed to prove non-inferiority to efavirenz+zidovudine/lamivudine as standard of care regimen in the 48 week intention-to-treat analysis. Using an assay with higher sensitivity for minority CXCR4-using (X4) HIV variants (the enhanced Trofile (TM) assay Monogram), non-inferiority was reached for the maraviroc-versus efavirenz-based combination. These data indicate the important impact of the sensitivity of tropism testing on treatment outcome of maraviroc-containing regimens. This paper discusses both the prospective and retrospective analyses of the MERIT data and highlights the impact of these results on daily practice in HIV care.".
- aggregation authorList BK136470.
- aggregation issue "4".
- aggregation startPage "115".
- aggregation volume "14".
- aggregation isDescribedBy 870320.
- aggregation similarTo LU-870320.